Oligodendroglioma - Pipeline Review, H2 2017

Date: September 30, 2017
Pages: 148
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: OE358DFEAECEN
Leaflet:

Download PDF Leaflet

Oligodendroglioma - Pipeline Review, H2 2017
Oligodendroglioma - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Oligodendroglioma - Pipeline Review, H2 2017, provides an overview of the Oligodendroglioma (Oncology) pipeline landscape.

Oligodendroglioma is a type of glioma (primary glial brain tumor). They often contain mineral deposits (called calcifications), areas of hemorrhage, and/or cysts. The most common symptoms are seizures, headaches, and personality changes. Other symptoms vary by location and size of the tumor. Treatment includes chemotherapy surgery and radiation therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Oligodendroglioma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Oligodendroglioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Oligodendroglioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Oligodendroglioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II and Phase I stages are 2, 6 and 11 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively.

Oligodendroglioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Oligodendroglioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Oligodendroglioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Oligodendroglioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Oligodendroglioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Oligodendroglioma (Oncology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Oligodendroglioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Oligodendroglioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Oligodendroglioma - Overview
Oligodendroglioma - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Oligodendroglioma - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Oligodendroglioma - Companies Involved in Therapeutics Development
AngioChem Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Cavion LLC
Celldex Therapeutics Inc
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Immatics Biotechnologies GmbH
Ipsen SA
Leadiant Biosciences Inc
Millennium Pharmaceuticals Inc
Northwest Biotherapeutics Inc
Novartis AG
Pfizer Inc
Tocagen Inc
Oligodendroglioma - Drug Profiles
abemaciclib - Drug Profile
afatinib dimaleate - Drug Profile
alisertib - Drug Profile
bevacizumab - Drug Profile
CDX-1401 - Drug Profile
Cellular Immunotherapy for Gliomas - Drug Profile
Cellular Immunotherapy for Oncology - Drug Profile
dasatinib - Drug Profile
DCVax-L - Drug Profile
flucytosine + TBio-01 - Drug Profile
flucytosine ER + vocimagene amiretrorepvec - Drug Profile
IMA-950 - Drug Profile
irinotecan hydrochloride - Drug Profile
irinotecan hydrochloride + TBio-02 - Drug Profile
mibefradil dihydrochloride - Drug Profile
nilotinib - Drug Profile
p28 - Drug Profile
paclitaxel trevatide - Drug Profile
palbociclib - Drug Profile
procarbazine hydrochloride - Drug Profile
TBX.OncV NSC - Drug Profile
Oligodendroglioma - Dormant Projects
Oligodendroglioma - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Oligodendroglioma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Oligodendroglioma - Pipeline by AngioChem Inc, H2 2017
Oligodendroglioma - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Oligodendroglioma - Pipeline by Bristol-Myers Squibb Co, H2 2017
Oligodendroglioma - Pipeline by Cavion LLC, H2 2017
Oligodendroglioma - Pipeline by Celldex Therapeutics Inc, H2 2017
Oligodendroglioma - Pipeline by Eli Lilly and Co, H2 2017
Oligodendroglioma - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Oligodendroglioma - Pipeline by Immatics Biotechnologies GmbH, H2 2017
Oligodendroglioma - Pipeline by Ipsen SA, H2 2017
Oligodendroglioma - Pipeline by Leadiant Biosciences Inc, H2 2017
Oligodendroglioma - Pipeline by Millennium Pharmaceuticals Inc, H2 2017
Oligodendroglioma - Pipeline by Northwest Biotherapeutics Inc, H2 2017
Oligodendroglioma - Pipeline by Novartis AG, H2 2017
Oligodendroglioma - Pipeline by Pfizer Inc, H2 2017
Oligodendroglioma - Pipeline by Tocagen Inc, H2 2017
Oligodendroglioma - Dormant Projects, H2 2017
Oligodendroglioma - Discontinued Products, H2 2017

LIST OF FIGURES

Number of Products under Development for Oligodendroglioma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

COMPANIES MENTIONED

AngioChem Inc
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Co
Cavion LLC
Celldex Therapeutics Inc
Eli Lilly and Co
F. Hoffmann-La Roche Ltd
Immatics Biotechnologies GmbH
Ipsen SA
Leadiant Biosciences Inc
Millennium Pharmaceuticals Inc
Northwest Biotherapeutics Inc
Novartis AG
Pfizer Inc
Tocagen Inc
Skip to top


Oligodendroglioma - Pipeline Review, H1 2017 US$ 2,000.00 Apr, 2017 · 130 pages
Mild Psoriasis - Pipeline Review, H2 2015 US$ 2,000.00 Nov, 2015 · 48 pages

Ask Your Question

Oligodendroglioma - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: